News
Patient randomization is nearly complete in Medicinova’s Phase 2b/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the ...
Answer ALS is backing a Louisiana collaboration aimed at using AI to accelerate drug discovery for ALS and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback